Geron Corporation Provides Update on Phase 3 IMpactMF Clinical Trial of Imetelstat in Relapsed/Refractory Myelofibrosis
Key Highlights
- ➤Geron will discontinue Phase 3 IMpactMF after DMC says overall-survival endpoint unlikely.
- ➤IMpactMF evaluated 327 JAK inhibitor relapsed/refractory myelofibrosis patients.
- ➤No new safety signals changed imetelstat’s known safety profile.
- ➤Geron remains focused on growing RYTELO demand and expanding LR-MDS access.
Expert Statements
Joseph E. Eid, M.D., Executive Vice President, Research and Development and Chief Medical Officer of Geron
“Given the recommendation from the DMC, we believe discontinuing our Phase3 IMpactMF trial at this time is the right course of action. We are deeply grateful to the patients and families, as well as the investigators and clinical teams whose dedication made this research possible.”
Joseph E. Eid, M.D., Executive Vice President, Research and Development and Chief Medical Officer of Geron
“Hematologic malignancies are complex diseases, with distinct biological characteristics and treatment challenges across patient populations. We remain committed to thoroughly evaluating the data, understanding what we can learn, and sharing insights that may help inform future research and address the significant unmet needs that remain.”
Harout Semerjian, President and Chief Executive Officer of Geron
“As we fully analyze the data from the IMpactMF trial, we remain committed to growing RYTELO demand in the U.S. and broadening access to eligible LR-MDS patients outside the U.S.”
Harout Semerjian, President and Chief Executive Officer of Geron
“We have a growing commercial business, a strong financial foundation, and a clear strategy to pursue innovation to create long-term value and build a leading hematology company.”
FOSTER CITY, Calif., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage hematology biopharmaceutical company, today announced the decision to discontinue the Phase 3 IMpactMF trial evaluating imetelstat in JAK inhibitor relapsed/refractory myelofibrosis. This decision was based on a recommendation from the independent Data Monitoring Committee (DMC).
The independent DMC advised Geron that the trial was unlikely to meet its primary endpoint of overall survival. There were no new safety signals observed in the trial that change the known safety profile of imetelstat or require additional safety monitoring. A detailed analysis of the data will be conducted, and study findings will be shared with the scientific community at a future date.
Get started
Create a free account to read the full story.